These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 20703958

  • 1. Does blockade of the Renin-Angiotensin-aldosterone system slow progression of all forms of kidney disease?
    Lattanzio MR, Weir MR.
    Curr Hypertens Rep; 2010 Oct; 12(5):369-77. PubMed ID: 20703958
    [Abstract] [Full Text] [Related]

  • 2. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    Tylicki L, Rutkowski P, Renke M, Larczyński W, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B.
    Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
    [Abstract] [Full Text] [Related]

  • 3. Beneficial long-term effect of aldosterone antagonist added to a traditional blockade of the renin-angiotensin-aldosterone system among patients with obesity and proteinuria.
    Morales E, Gutiérrez E, Caro J, Sevillano A, Rojas-Rivera J, Praga M.
    Nefrologia; 2015 Sep; 35(6):554-61. PubMed ID: 26519114
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of the renin-angiotensin-aldosterone system for cerebrorenal protection.
    Lambers Heerspink HJ.
    Contrib Nephrol; 2013 Sep; 179():7-14. PubMed ID: 23652444
    [Abstract] [Full Text] [Related]

  • 5. Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade.
    Shenoy SV, Nagaraju SP, Bhojaraja MV, Prabhu RA, Rangaswamy D, Rao IR.
    Nephrology (Carlton); 2021 Nov; 26(11):858-871. PubMed ID: 34176194
    [Abstract] [Full Text] [Related]

  • 6. Blockade of the renin-angiotensin-aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: a systematic review and meta analysis of randomized controlled trials.
    Khatib R, Joseph P, Briel M, Yusuf S, Healey J.
    Int J Cardiol; 2013 Apr 30; 165(1):17-24. PubMed ID: 22421406
    [Abstract] [Full Text] [Related]

  • 7. Renin-angiotensin-aldosterone system inhibitors in heart failure.
    Shearer F, Lang CC, Struthers AD.
    Clin Pharmacol Ther; 2013 Oct 30; 94(4):459-67. PubMed ID: 23852393
    [Abstract] [Full Text] [Related]

  • 8. Therapeutic measures in proteinuric nephropathy.
    Praga M.
    Kidney Int Suppl; 2005 Dec 30; (99):S137-41. PubMed ID: 16336567
    [Abstract] [Full Text] [Related]

  • 9. The renin-angiotensin-aldosterone system blockade in patients with advanced diabetic kidney disease.
    Bermejo S, García CO, Rodríguez E, Barrios C, Otero S, Mojal S, Pascual J, Soler MJ.
    Nefrologia (Engl Ed); 2018 Dec 30; 38(2):197-206. PubMed ID: 29102270
    [Abstract] [Full Text] [Related]

  • 10. Monotherapy of RAAS blockers and mobilization of aldosterone: A mechanistic perspective study in kidney disease.
    Gupta G, Dahiya R, Singh Y, Mishra A, Verma A, Gothwal SK, Aljabali AAA, Dureja H, Prasher P, Negi P, Kapoor DN, Goyal R, Tambuwala MM, Chellappan DK, Dua K.
    Chem Biol Interact; 2020 Feb 01; 317():108975. PubMed ID: 32032593
    [Abstract] [Full Text] [Related]

  • 11. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease.
    Remuzzi G, Perico N, Macia M, Ruggenenti P.
    Kidney Int Suppl; 2005 Dec 01; (99):S57-65. PubMed ID: 16336578
    [Abstract] [Full Text] [Related]

  • 12. Cardiorenal protection during chronic renin-angiotensin-aldosterone system suppression: evidences and caveats.
    Ruiz-Hurtado G, Ruilope LM.
    Eur Heart J Cardiovasc Pharmacother; 2015 Apr 01; 1(2):126-31. PubMed ID: 27533982
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis.
    Susantitaphong P, Sewaralthahab K, Balk EM, Eiam-ong S, Madias NE, Jaber BL.
    Am J Hypertens; 2013 Mar 01; 26(3):424-41. PubMed ID: 23382494
    [Abstract] [Full Text] [Related]

  • 14. Effects of Renin-Angiotensin-Aldosterone System Blockade in Patients with End-Stage Renal Disease.
    Slomka T, Lennon ES, Akbar H, Gosmanova EO, Bhattacharya SK, Oliphant CS, Khouzam RN.
    Am J Med Sci; 2016 Mar 01; 351(3):309-16. PubMed ID: 26992264
    [Abstract] [Full Text] [Related]

  • 15. Renalism with Renin Angiotensin Aldosterone System Blockade: What Is the Consensus in Advanced Chronic Kidney Disease?
    Turino Miranda K, Ahmed SB.
    Can J Cardiol; 2024 Sep 01; 40(9):1729-1731. PubMed ID: 38777038
    [No Abstract] [Full Text] [Related]

  • 16. Effects of RAAS Inhibitors in Patients with Kidney Disease.
    Zhang F, Liu H, Liu D, Liu Y, Li H, Tan X, Liu F, Peng Y, Zhang H.
    Curr Hypertens Rep; 2017 Aug 08; 19(9):72. PubMed ID: 28791529
    [Abstract] [Full Text] [Related]

  • 17. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?
    Werner C, Pöss J, Böhm M.
    Drugs; 2010 Jul 09; 70(10):1215-30. PubMed ID: 20568830
    [Abstract] [Full Text] [Related]

  • 18. Mineralcorticoid receptor blockers in chronic kidney disease.
    Erraez S, López-Mesa M, Gómez-Fernández P.
    Nefrologia (Engl Ed); 2021 Jul 09; 41(3):258-275. PubMed ID: 36166243
    [Abstract] [Full Text] [Related]

  • 19. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Bolignano D, Palmer SC, Navaneethan SD, Strippoli GF.
    Cochrane Database Syst Rev; 2014 Apr 29; (4):CD007004. PubMed ID: 24782282
    [Abstract] [Full Text] [Related]

  • 20. Benefits and Risks of Continuing Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Antagonists, and Mineralocorticoid Receptor Antagonists during Hospitalizations for Acute Heart Failure.
    Oliveros E, Oni ET, Shahzad A, Kluger AY, Lo KB, Rangaswami J, McCullough PA.
    Cardiorenal Med; 2020 Apr 29; 10(2):69-84. PubMed ID: 32062648
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.